Literature DB >> 15102928

Development of bombesin analogs with conformationally restricted amino acid substitutions with enhanced selectivity for the orphan receptor human bombesin receptor subtype 3.

Samuel A Mantey1, David H Coy, Laurence K Entsuah, Robert T Jensen.   

Abstract

The human bombesin receptor subtype 3 (hBRS-3) orphan receptor, which has a high homology to bombesin (Bn) receptors [gastrin-releasing peptide (GRP) and neuromedin B (NMB) receptors], is widely distributed in the rat central nervous system. Its natural ligand or role in physiology is unknown due to lack of selective ligands. Its target disruption leads to obesity, diabetes, and hypertension. A synthetic high-affinity agonist, [D-Tyr6,beta-Ala11,Phe13,Nle14]Bn(6-14), has been described, but it is nonselective for hBRS-3 over other Bn receptors; however, substitution of (R)- or (S)-amino-3-phenylpropionic acid (Apa) for beta-Ala11 resulted in a modestly selective ligand. In the present study, we have attempted to develop a more selective hBRS-3 ligand by using two strategies: substitutions on phenyl ring of Apa11 and the substitution of other conformationally restricted amino acids into position 11 of [D-Tyr6,beta-Ala11,Phe13,Nle14]Bn(6-14). Fifteen analogs were synthesized and affinities were determined for hBRS-3 and Bn receptors (hGRP-R and hNMB-R). Selective analogs were tested for their ability to activate each receptor by stimulating phospholipase C. One analog, [D-Tyr6,Apa-4Cl,Phe13,Nle14]Bn(6-14), retained high affinity for the hBRS-3 (Ki=8 nM) and had enhanced selectivity (>230-fold) for hBRS-3 over hGRP-R or hNMB-R. This analog specifically interacted with hBRS-3, fully activated hBRS-3 receptors, and was a potent agonist at the hBRS-3 receptor. This enhanced selectivity should allow this analog to be useful for investigating the possible role of hBRS-3 in physiological or pathological processes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15102928     DOI: 10.1124/jpet.104.066761

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  17 in total

1.  Pharmacology of putative selective hBRS-3 receptor agonists for human bombesin receptors (BnR): affinities, potencies and selectivity in multiple native and BnR transfected cells.

Authors:  Veronica Sancho; Terry W Moody; Samuel A Mantey; Alessia Di Florio; Hirotsugu Uehara; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2010-05-12       Impact factor: 3.750

Review 2.  Insights into bombesin receptors and ligands: Highlighting recent advances.

Authors:  Irene Ramos-Álvarez; Paola Moreno; Samuel A Mantey; Taichi Nakamura; Bernardo Nuche-Berenguer; Terry W Moody; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2015-05-11       Impact factor: 3.750

Review 3.  Bombesin receptor subtype 3 as a potential target for obesity and diabetes.

Authors:  Nieves González; Paola Moreno; Robert T Jensen
Journal:  Expert Opin Ther Targets       Date:  2015-06-12       Impact factor: 6.902

4.  Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.

Authors:  Hirotsugu Uehara; Nieves González; Veronica Sancho; Samuel A Mantey; Bernardo Nuche-Berenguer; Tapas Pradhan; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2011-06-28       Impact factor: 3.750

5.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

6.  Development and Characterization of a Novel, High-Affinity, Specific, Radiolabeled Ligand for BRS-3 Receptors.

Authors:  Irene Ramos-Alvarez; Lingaku Lee; Samuel A Mantey; Robert T Jensen
Journal:  J Pharmacol Exp Ther       Date:  2019-04-10       Impact factor: 4.030

7.  A selective human bombesin receptor subtype-3 peptide agonist mediates CREB phosphorylation and transactivation.

Authors:  Xiaoqun Qin; Xiangping Qu; David Coy; H Christian Weber
Journal:  J Mol Neurosci       Date:  2011-11-30       Impact factor: 3.444

8.  Molecular basis for high affinity and selectivity of peptide antagonist, Bantag-1, for the orphan BB3 receptor.

Authors:  Taichi Nakamura; Irene Ramos-Álvarez; Tatiana Iordanskaia; Paola Moreno; Samuel A Mantey; R T Jensen
Journal:  Biochem Pharmacol       Date:  2016-06-23       Impact factor: 5.858

9.  Molecular basis for agonist selectivity and activation of the orphan bombesin receptor subtype 3 receptor.

Authors:  Nieves Gonzalez; Simon J Hocart; Sergio Portal-Nuñez; Samuel A Mantey; Tomoo Nakagawa; Enrique Zudaire; David H Coy; Robert T Jensen
Journal:  J Pharmacol Exp Ther       Date:  2007-11-15       Impact factor: 4.030

10.  Anticancer activity of a peptide combination in gastrointestinal cancers targeting multiple neuropeptide receptors.

Authors:  Manu Jaggi; Sudhanand Prasad; Anu T Singh; R Praveen; Sarjana Dutt; Archana Mathur; Rajan Sharma; Neena Gupta; Rinku Ahuja; Rama Mukherjee; Anand C Burman
Journal:  Invest New Drugs       Date:  2008-01-24       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.